Table 2.
Laboratory Findings Among Patients With COVID-19 Stratified Into Those With Preexisting Liver Disease and Without Liver Disease
| Laboratory findings | COVID-19 with liver disease (n = 250) |
COVID-19 without liver disease (n = 2530) |
||
|---|---|---|---|---|
| Baseline | After COVID-19 | Baseline | After COVID-19 | |
| Liver chemistries (serum, plasma, or blood) | ||||
| ALT, U/L, mean ± SD (n) | 30 ± 24 (220) | 100 ± 444 (130) | 21 ± 17 (1520) | 80 ± 227 (70) |
| ALT > 50 U/L, % (n/total) | 46.1 (60/130) | 50.6 (390/770) | ||
| ALT >150 U/L, % (n/total) | 15.4 (20/130) | 11.7 (90/770) | ||
| AST, U/L, mean ± SD (n) | 34 ± 26 (220) | 221 ± 1799 (130) | 22 ± 20 (1520) | 133 ± 678 (770) |
| AST elevation > 50 U/L, % (n/total) | 61.5 (80/130) | 67.5 (520/770) | ||
| AST elevation > 150 U/L, % (n/total) | 15.4 (20/130) | 16.9 (130/770) | ||
| GGT, U/L, mean ± SD (n) | 219 ± 485 (70) | 278 ± 521 (10) | 44 ± 54 (70) | 99 ± 146 (30) |
| GGT > 50 U/L, % (n/total) | 100 (10/10) | 66.6 (20/30) | ||
| Total bilirubin, mg/dL, mean ± SD (n) | 0.8 ± 1.3 (220) | 1.2 ± 2.9 (120) | 0.5 ± 0.3 (1510) | 0.8 ± 1.2 (770) |
| Total bilirubin > 2 mg/dL, % (n/total) | 25.0 (30/120) | 9.1 (70/770) | ||
| Alkaline phosphatase, U/L, mean ± SD (n) | 112 ± 111 (220) | 153 ± 175 (120) | 778 ± 29 (1520) | 93 ± 62 (770) |
| Alkaline phosphatase > 150 U/L, % (n/total) | 41.6 (50/120) | 15.6 (120/770) | ||
| Serum albumin, g/dL, mean ± SD (n) | 3.9 ± 0.8 (220) | 2.6 ± 0.8 (120) | 4.1 ± 0.6 (1510) | 2.5 ± 0.7 (770) |
| Metabolic panel (serum, plasma, or blood) | ||||
| Sodium, mEq/L, mean ± SD (n) | 139 ± 3 (230) | 137 ± 5 (130) | 140 ± 3 (1660) | 137 ± 5 (880) |
| Potassium, mEq/L, mean ± SD (n) | 4.0 ± 0.4 (230) | 4.1 ± 0.4 (130) | 4.3 ± 0.8 (1660) | 4.1 ± 1.0 (880) |
| Creatinine, mg/dL, mean ± SD (n) | 1.2 ± 1.0 (230) | 1.8 ± 2.1 (130) | 1.0 ± 1.0 (1680) | 1.8 ± 2.1 (880) |
| Complete blood count, mean ± SD (n) | ||||
| Hemoglobin, g/dL | 12.2 ± 2.4 (220) | 10.4 ± 2.1 (130) | 12.9 ± 1.9 (1660) | 11.08 ± 2.2 (860) |
| Leukocytes/μL | 7.6 ± 3.6 (220) | 8.8 ± 5.9 (130) | 7.4 ± 2.9 (1660) | 9.7 ± 6.3 (860) |
| Platelets/μL | 229 ± 92 (220) | 237 ± 122 (130) | 253 ± 78 (1660) | 276 ± 123 (860) |
| Lymphocytes/μL | 2.4 ± 4.4 (130) | 1.9 ± 3.7 (50) | 2.2 ± 2.9 (800) | 2.5 ± 5.8 (220) |
| Neutrophils/100 leukocytes | 63 ± 12 (110) | 70 ± 16 (50) | 61 ± 12 (800) | 69.2 ± 13 (230) |
| Coagulation profile, mean ± SD (n) | ||||
| Prothrombin time, s | 12.5 ± 3.45 (170) | 14.94 ± 4.81 (50) | 12 ± 3.62 (650) | 14.03 ± 7.36 (250) |
| Activated partial thromboplastin time, s | 31.0 ± 10.9 (140) | 39.0 ± 16.4 (30) | 29.1 ± 8.2 (540) | 38.9 ± 15.7 (220) |
| Inflammatory, infectious and other markers (serum, plasma, or blood), mean ± SD (n) | ||||
| Ferritin, ng/mL | 371 ± 94 (130) | 1925 ± 2567 (30) | 234 ± 735 (380) | 2225 ± 6179 (270) |
| C-reactive protein, mg/L | 25 ± 53 (110) | 131 ± 103 (70) | 17 ± 40 (370) | 130 ± 113 (570) |
| Erythrocyte sedimentation rate, mm/h | 36 ± 29 (110) | 56 ± 42 (10) | 24 ± 24 (440) | 71 ± 35 (70) |
| Lactate dehydrogenase, U/L | 270 ± 159 (80) | 440 ± 568 (30) | 260 ± 460 (190) | 555 ± 747 (270) |
| Interleukin 6, pg/mL | 86 ± 111 (10) | 99 ± 188 (50) | ||
| D-dimer, μg/mL | 1.0 ± 0.3 (10) | 2.9 ±3.5 (30) | ||
| Creatinine kinase, U/L | 1068 ± 2797 (20) | 1032 ± 3358 (170) | ||
| Procalcitonin, ng/mL | 3.4 ± 5.3 (20) | 2.3 ± 8.3 (220) | ||
NOTE. Laboratory findings are compared before and after COVID-19 diagnosis.
GGT, gamma glutamyl transferase.